Affiliation:
1. Maternal, Child and Adolescent Health Program Burnet Institute Melbourne Victoria Australia
2. Policy Cures Research Sydney New South Wales Australia
3. Department of Obstetrics and Gynaecology University of Melbourne Heidelberg Victoria Australia
4. Concept Foundation Geneva Switzerland
5. Public Health Agency of Canada Ottawa Ontario Canada
6. School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
Abstract
AbstractObjectiveThe Accelerating Innovation for Mothers project established a new database of candidate medicines under development between 2000 and 2021 for five pregnancy‐related conditions, including fetal growth restriction. The objective was to assess medicines for fetal growth restriction and their potential for clinical use globally.DesignLandscape analysis.SettingGlobal (focus on low‐ and middle‐income countries, LMICs).SampleDrugs, dietary supplements and biologics under investigation for prevention or treatment of fetal growth restriction.MethodsA research pipeline database of medicines was created through searching AdisInsight, PubMed and various grant and clinical trial databases. Analysis of clinical and preclinical candidates were descriptive.Main Outcomes MeasuresFetal growth restriction candidates in clinical development were identified and ranked as high, medium or low potential based on prespecified criteria, including efficacy, safety and accessibility.ResultsOf the 444 unique candidates in the database across all five pregnancy‐related conditions, 63 were for fetal growth restriction. Of these, 31 were in clinical development (phases I, II or III) and 32 were in preclinical development. Three candidates, aspirin, l‐arginine and vitamin D, were ranked as having high potential as preventive agents. There were no high‐potential candidates for treating fetal growth restriction, although five candidates were ranked as having medium potential: allylestrenol, dalteparin, omega‐3 fatty acids, tadalafil, and United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP).Conclusionsl‐Arginine, aspirin and vitamin D are promising, high‐potential preventative agents for fetal growth restriction. Based on the medicines pipeline, new pharmacological agents for fetal growth restriction are unlikely to emerge in the near future.
Funder
Bill and Melinda Gates Foundation
Subject
Obstetrics and Gynecology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献